Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Regular Article
Comparison of Adverse Event Incidence between Japanese and Non-Japanese: A Systematic Review and Meta-analysis for Patients with Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, and Atrial Fibrillation/Venous Thromboembolism
Satomi Sakurai , Kazuhiro Matsui, Mamoru Narukawa
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2026 Volume 49 Issue 11 Pages 1884-1893

Details
Abstract

Enhancing diversity in clinical trial populations is increasingly important, particularly for underrepresented populations. We focused on adverse events (AEs) that have been reported to be more frequent in Japanese than in non-Japanese populations and assessed their plausibility. We conducted a systematic review and random-effects meta-analysis of 24 multiregional clinical trials (MRCTs): 9 in rheumatoid arthritis (RA), 11 in chronic obstructive pulmonary disease (COPD), and 4 in atrial fibrillation (AF) or venous thromboembolism (VTE). Pooled estimates of the odds ratios (ORs) compared the incidence of targeted AEs between Japanese and non-Japanese participants using a random-effects model. For Janus kinase inhibitors in RA, the OR for the incidence of herpes zoster was 2.50 (95% confidence interval [CI]: 1.18–5.29, p = 0.0172), suggesting more frequent occurrence in Japanese participants than in non-Japanese participants. The incidence of pneumonia was statistically higher in Japanese in most COPD treatment groups and in the placebo group (OR 4.03 [95% CI: 1.33–12.19, p = 0.0135] for placebo). For direct oral anticoagulants for AF/VTE, the OR for major bleeding was 1.19 (95% CI: 0.91–1.56, p = 0.2105), with no statistically significant difference observed between Japanese and non-Japanese participants. This meta-analysis supported a higher incidence of herpes zoster in Japanese patients with RA, whereas the findings for pneumonia in COPD should be interpreted cautiously, and no statistically significant difference was observed for major bleeding in AF/VTE. Broader inclusion of Japanese participants in MRCTs may improve the interpretability of safety findings and the understanding of population-related differences in drug safety profiles.

Fullsize Image
Content from these authors
© 2026 The Author(s).
Published by The Pharmaceutical Society of Japan

This article is licensed under a Creative Commons [Attribution-NonCommercial 4.0 International] license.
https://creativecommons.org/licenses/by-nc/4.0/
Previous article Next article
feedback
Top